GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
GlaxoSmithKline PLC (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Business Wire
Reduction observed in RSV-related hospitalizations in adults aged =60 years1An observed reduction in major adverse cardiovascular events* in adults aged =60 years?2 during RSV-related hospitalizationRisk reduction observed against severe flare-ups of chronic obstructive pulmonary disease (COPD) and asthma†2 during RSV-related hospitalization PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy. GSK is presenting 19 abstracts at the congress and supporting a further 3, reflecting GSK’s leadership in research and prevention of RSV. AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.Hospitalization pl
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GlaxoSmithKline PLC news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK (NYSE:GSK) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- GSK (NYSE:GSK) had its "hold" rating reaffirmed by analysts at TD Cowen.MarketBeat
- GSK (NYSE:GSK) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating on the stock.MarketBeat
- GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026Business Wire
- GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 MillionBusiness Wire
GSK
Sec Filings
- 2/18/26 - Form 6-K
- 2/17/26 - Form 6-K
- 2/17/26 - Form 6-K
- GSK's page on the SEC website